Robert F. Kennedy Jr., the Health and Human Services Secretary, plans to cut the size of the department by 10,000 full-time employees, The Wall Street Journal’s Liz Essley Whyte and Natalie Andrews reports. The job cuts, which are set to be announced on Thursday, will be spread across departments tasked with responding to disease outbreaks, approving new drugs, providing insurance for the poorest Americans and more, and are in addition to roughly 10,000 employees who opted to leave the department since President Trump took office, through voluntary separation offers, according to documents viewed by the publication. The voluntary departures and the plan would result in the department shedding about one-quarter of its workforce, if fully implemented. Publicly traded companies in the space include AstraZeneca (AZN), Bristol Myers (BMY), Eli Lilly (LLY), GSK (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- AnaptysBio could have positive read from J&J abstracts, says Guggenheim
- J&J says Rybrevant/Lazcluze outperforms osimertinib OS in Phase 3 study
- U.S. to end funding for child vaccines in developing countries, NY Times reports
- Large pharma M&A deals stalling amid volatile policies, Reuters reports
- Needham medtech & diagnostics analyst holds analyst/industry conference call